Professor, Internal Medicine, Washington University in St. Louis School of Medicine
Internal Medicine
Dr. Brian F. Gage, MD
|
|
Give Review
Brian F. Gage works in the field of Internal Medicine. He graduated from University of California San Diego School of Medicine. University of California San Diego School of Medicine has a rank of 17 in research and a 19 in primary care Dr. Brian F. Gage is a published doctor and has 59 publications published. The lastest was: 'A tool to assess risk of de novo opioid abuse or dependence.' Dr. Brian F. Gage is registered with Medicare.
Publications
- A tool to assess risk of de novo opioid abuse or dependence.
- Improving accuracy of International Classification of Diseases codes for venous thromboembolism in administrative data.
- Clinical Benefit of American College of Chest Physicians versus European Society of Cardiology Guidelines for Stroke Prophylaxis in Atrial Fibrillation.
- Clinical outcomes with use of erythropoiesis stimulating agents in patients with the HeartMate II left ventricular assist device.
- Risk model for estimating the 1-year risk of deferred lesion intervention following deferred revascularization after fractional flow reserve assessment.
- Letter in response to "Use of preoperative cardiac troponin T to identify patients at risk for acute myocardial infraction and long-term mortality after major noncardi...
- A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing.
- Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial.
- Risk factors for inpatient venous thromboembolism despite thromboprophylaxis.
- High-sensitivity cardiac troponin T in prediction and diagnosis of myocardial infarction and long-term mortality after noncardiac surgery.
- Physician and nurse acceptance of technicians to screen for geriatric syndromes in the emergency department.
- American Heart Association Atrial Fibrillation Research Summit: A Conference Report From the American Heart Association.
- Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation.
- Genetic warfarin dosing: tables versus algorithms.
- Pediatric warfarin practice and pharmacogenetic testing.
- Cost-effectiveness of outpatient cardiac monitoring to detect atrial fibrillation after ischemic stroke.
- Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study).
- Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy.
- Can we rely on RE-LY?
- Anemia: an independent predictor of death and hospitalizations among elderly patients with atrial fibrillation.
- Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADve...
- Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.
- Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose.
- CYP4F2 genetic variant alters required warfarin dose.
- Optimal initial dose adjustment of warfarin in orthopedic patients.
- Genetic-based dosing in orthopedic patients beginning warfarin therapy.
- Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified?
- Anemia does not predict mortality in elderly patients with heart failure.
- An invasive strategy is associated with decreased mortality in patients 80 years and older with acute myocardial infarction.
- Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation.
- Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF).
- Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2.
- Improving adherence to coronary heart disease secondary prevention medication guidelines at a community hospital.
- Pharmacogenetics-based coumarin therapy.
- Use of EPO in critically ill patients with acute renal failure requiring renal replacement therapy.
- Comorbidity indices to predict mortality from Medicare data: results from the national registry of atrial fibrillation.
- Preference-based antithrombotic therapy in atrial fibrillation: implications for clinical decision making.
- Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.
- Reliability for grading acute rejection and airway inflammation after lung transplantation.
- Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall.
- Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors.
- Implantable cardioverter-defibrillator therapy improves long-term survival in patients with unexplained syncope, cardiomyopathy, and a negative electrophysiologic study.
- Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation.
- Simplified peak power reserve in patients with an implantable cardioverter-defibrillator and advanced heart failure.
- Pharmacology and pharmacogenetics of warfarin and other coumarins when used with supplements.
- Construction and validation of an automated model for the early identification of patients hospitalized for heart failure.
- Yield of surveillance bronchoscopy for acute rejection and lymphocytic bronchitis/bronchiolitis after lung transplantation.
- Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin.
- Effect of warfarin nonadherence on control of the International Normalized Ratio.
- The management of anticoagulants in the periendoscopic period for patients with atrial fibrillation: a decision analysis.
- Randomized trial of warfarin nomograms.
- Perioperative reduction of the warfarin dose.
- Cost-savings analysis of using a portable coagulometer for monitoring homebound elderly patients taking warfarin.
- Predictors of mortality in younger and older patients with heart failure and preserved or reduced left ventricular ejection fraction.
- Outpatient treatment of acute venous thromboembolic disease.
- Warfarin dose reduction vs watchful waiting for mild elevations in the international normalized ratio.
- Risk factors for bleeding in patients taking coumarins.
- Substitution of generic warfarin for Coumadin in an HMO setting.
Schools
University of California At San Diego
Good SamaritanVamc
Barnes Hospital
Palo Alto Va Stanford University
Doctors Specialties
- Internal Medicine
Accepted Insurances
Education
-
Banner Good Samaritan Medical Center -
Washington University - Barnes-Jewish Hospital -
University of California San Diego School of Medicine
Hospital
-
Barnes-Jewish Hospital
Drug Facts
| NPI NUMBER | 1467470195 | |
| NPPES Provider LastName | GAGE | |
| NPPES Provider FirstName | BRIAN | |
| NPPES Provider ZIPCode | 631101000 | |
| NPPES Provider State | MO | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 70.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1467470195 |
| Last Name Of The Provider | GAGE |
| First Name Of The Provider | BRIAN |
| View All |
Similar Doctors
|
|
Dr. Victoria L. Jansen, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rajeshwar Peddi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard A. Bligh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John H. Kissel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel B. Green, MD |
|
|
Dr. Megan E. Wren, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Francis X. Jana, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Iqbal I. Amin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rama D. Bandi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel Gaitan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Melissa W. Sum, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew C. Loftspring, MD
This Doctor is OpenDoctor Recommended.
|